Mifepristone as a Psychopharmacologic Agent: Consideration of Efficacy, Plasma Levels, and Mechanism of Action

The reanalysis by Block et  al. (1) of the major controlled trials of the glucocorticoid receptor (GR) antagonist mifepristone in the treatment of psychotic depression (PD) brings the field another step closer to being able to utilize this novel treatment. The five trials analyzed were sponsored by Corcept Therapeutics (Menl o Park, CA) and nearly identical with respect to inclusion criteria, assessments, and drug regimen (1 week experimental treatment before antidepressant treatment) but differed in mifepristone dosing (1).

Source: Biological Psychiatry - June 18, 2018 Category: Psychiatry Authors: Julia A. Golier, Rachel Yehuda Tags: Commentary Source Type: research